The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2021 | Evolution of multiple myeloma treatment in Norway
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, outlines the evolution of multiple myeloma treatment in Norway. Dr Schjesvold highlights use of the lenalidomide, bortezomib and dexamethasone triplet in the first-line setting, as well as discussing the uptake of various diagnostic tools to improve multiple myeloma treatment. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.
